ReviewCurrent heart failure reports2025
Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates.
Review in Current heart failure reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- C-reactive protein-to-albumin ratio and the mortality of patients with heart failure: a meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Review
- Human biomarker navigator.iMeta · 2026Review
- Correlation Between the High-Sensitivity C-Reactive Protein-to-Albumin Ratio and All-Cause Mortality in Patients With Acute Exacerbation of Chronic Heart Failure.Clinical cardiology · 2026Article
- Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.Kidney international reports · 2026Review
- Beyond Autonomic Modulation: Baroreflex Activation Therapy and the Neuroimmune Axis in HFrEF.JACC. Case reports · 2026Article
- Subclinical Inflammation in Ischemic Heart Disease and Its Role in the Transition to Heart Failure.Life (Basel, Switzerland) · 2026Review
- Neutrophil Percentage-to-Albumin Ratio as a Novel Predictor of Diuretic Resistance and Mortality in Patients with Heart Failure with Preserved Ejection Fraction.Anatolian journal of cardiology · 2026Article
- Development and validation of a clinically available risk model for medium-to-high opioid consumption after total knee arthroplasty.American journal of translational research · 2026Article
- Targeting IL-1β: a potential strategy for alleviating the immunopathology of aortic aneurysms.Frontiers in immunology · 2026Review
- From acute diagnosis to longitudinal risk stratification: a paradigm shift in the clinical role of cardiac biomarkers.Frontiers in cardiovascular medicine · 2026Article
- The role of the NLRP3 inflammasome in hypertension-related chronic heart failure and its potential therapeutic targets.Frontiers in immunology · 2026Article
- Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeart failure (HF) remains a leading cause of morbidity and mortality worldwide. Increasing evidence highlights that systemic low-grade inflammation is a key pathophysiological driver of HF. This review seeks to examine the diagnostic and therapeutic relevance of inflammatory biomarkers - specifically interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) - and evaluate their potential for improving risk stratification and enabling personalized treatment approaches in HF. RECENT
findingsIL-6 and hsCRP have emerged as important markers of residual inflammatory risk in HF. Elevated levels of these biomarkers are associated with increased risk of incident HF and adverse outcomes in established disease. While hsCRP is as a downstream marker of inflammation with no causal involvement, Mendelian randomization studies support a causal role of IL-6 signaling in the development of HF and coronary artery disease. Recent and ongoing clinical trials support the concept of targeting inflammatory pathways as a therapeutic strategy in selected HF populations. Inflammatory biomarkers, particularly IL-6 and hsCRP, are promising tools for advancing precision medicine in HF by improving individual risk assessment and guiding anti-inflammatory interventions. Further large-scale studies are needed to validate the integration of inflammatory biomarkers into clinical algorithms for HF and explore their potential role in future guideline recommendations and personalized prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.